Point‐of‐Care Testing in Sickle Cell Disease by Kanter, Julie
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 4
Point‐of‐Care Testing in Sickle Cell Disease
Julie Kanter
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/64862
Provisional chapter
Point‐of‐Care Testing in Sickle Cell Disease
Julie Kanter
Additional information is available at the end of the chapter
Abstract
Sickle cell disease is one of the most common inherited blood disorders. Universal
screening and central  laboratory diagnostics  have improved early  identification of
affected  individuals  and  helped  to  reduce  childhood  mortality  in  high‐resource
countries. Additional methods of centralized diagnostics have also been developed in
some low resource areas in partnership with private companies, local governments and
academic  US‐based  institutions.  However,  these  techniques  require  expansive
infrastructure and government partnership for success. Thus, many individuals living
in low‐resource settings are often not diagnosed until late childhood when they present
with clinical symptoms. In addition, confirmation of disease in affected individuals in
the urgent care setting remains limited in both high‐ and low‐resource areas due to the
use of batched testing methods. All of the current diagnostic methods rely on advanced
laboratory  systems and are  often  prohibitively  expensive  and time‐consuming.  To
address this need and improve the capacity for timely diagnosis, novel methods for
point‐of‐care testing for sickle cell disease are currently in process.
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1. Introduction
Approximately 5% of the world's population carries traits for hemoglobin disorder (majority
sickle cell disease, thalassemia). The global incidence of sickle cell disease (SCD) is 300,000
births/year of which 90% are estimated to occur in sub‐Saharan African and India, many of
whom reside in low‐resource areas. In many of these areas, 50–80% of children die before five
years of age [1]. In contrast, a small margin of affected individuals are born in the USA,
England, France and other high‐resource countries where 98% of children are living >18 years
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
of age. In these high‐resource countries, early diagnosis remains a key reason for the improved
longevity [2, 3].
Newborn screening provides an early diagnosis of SCD which has demonstrated efficacy in
reducing infant mortality through initiation of penicillin prophylaxis and delivery of care/
education prior to the onset of clinical complications [4, 5]. However, current newborn
screening programs are dependent on central laboratories with capabilities to perform cost‐
efficient, high‐throughput screening [6]. In addition to high‐cost laboratory equipment, these
programs require complex work‐flow including skilled individuals, sample transport and
advanced systems of medical care. Additionally, most newborn screening samples are
collected at outlying hospitals and are shipped to centralized laboratories where tests are
batched and run on a scheduled basis and results are then sent to primary care providers or
public health officials to communicate with affected families. Screening is two‐tiered starting
with testing in the hospital and complementary, confirmatory testing performed at follow‐up
to confirm the diagnosis (and validate the sample was sent on the correct patient). Thus, all
individuals are tested while in the hospital during the newborn period, and the results are
often not available for communication until several weeks after discharge. While systems of
care exist in many developed countries for communicating these results, these options are not
available in other, less resourced areas. Even in some high‐resource areas, it can also be difficult
to find the newborn and bring them back to the provider for confirmatory testing.
While newborn screening is limited in low‐resource areas, many high‐resource countries are
unable to diagnose and confirm sickle cell disease at the point of care (POC). Similar to tests
used during newborn screening, diagnostic tests for SCD are expensive and time consum‐
ing. As a result, the testing is often batched and run on specific days with limited availability
for diagnosis at the point of care or when the patient presents. While this limitation does not
affect most patients who have been previously identified within a health system, the inabili‐
ty to confirm the diagnosis at the point of care can lead to delays in treatment in outside hos‐
pitals (where the individual is not usually treated) or inappropriate treatment for an affected
individual. Due to the painful nature of this disease, many patients face undue stigmatiza‐
tion for having sickle cell disease. Without “proof” of disease, patients may not be able to
receive the care they need in a timely manner. Conversely, there are also anecdotal reports of
individuals without SCD who falsely claim to be affected by the condition to receive opioid
therapy in the emergency room setting. For those patients not established within a hospital
system, a point‐of‐care test may enhance the ability of acute care physicians to provide ap‐
propriate therapy.
Research has clearly demonstrated that the health burden of hemoglobin disorders can be
reduced through screening and early diagnosis, prevention and management [5, 7, 8]. While
these cost‐effective lifesaving strategies/therapies are already known, many are not univer‐
sally available [9]. Thus, options for enhancing access to early diagnosis include the develop‐
ment of centralized laboratories in low‐resource areas and novel point‐of‐care testing
method which remain in development.
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2. Traditional diagnostic testing in SCD
The diagnosis of a hemoglobin disorder is usually performed by confirmatory testing in
hospital, private or academic laboratories. The majority of current labs in high‐resource areas
utilize methods of protein chemistry methods such as isoelectric focusing (IEF) or high‐
performance liquid chromatography (HPLC) and (Sebia) capillary electrophoresis (CE) [10].
Some additional laboratories utilize hemoglobin electrophoresis with either cellulose acetate
or citrate agar. Specifically, acid citrate agar is used for conformation of hemoglobin SC disease.
See Table 1 for a list of testing methods.
Isoelectric focusing utilizes agarose gels to separate hemoglobin (Hb) fractions and variants
based on their isoelectric points [11]. Hb A and Hb F are clearly resolved by this method. Hb
C can also be distinguished from Hb E and Hb O, and Hb S can be distinguished from Hb.
High‐performance liquid chromatography separates hemoglobin in sample by passing them
through a column filled with a solid adsorbent material. Specifically, HPLC uses the principles
of cation exchange for the separation and determination of the relative percentage of normal
and abnormal hemoglobin. Each component in the sample interacts slightly differently with
the adsorbent material, causing different flow rates for the different components and leading
to the separation of the components as they flow out the column. This is the method used to
identify and quantify relative fractions of Hb F, Hb A2, Hb S, Hb C, Hb Barts and other Hb
variants. HPLC is also used to quantify Hb A2 and Hb F for carrier screening [12, 13].
Hemoglobin electrophoresis at alkaline or acidic pH can be used as a primary or confirmatory
method of identification. Electrophoresis separates molecules based on size and charge. Dif‐
ferent hemoglobin has a different charge, and according to those charges and the amount,
hemoglobin moves at different speeds in the gel whether in alkaline gel or acid gel. This
method separates hemoglobin based on the relative mobility of the variant hemoglobin into
characteristic bands [10, 14].
Novel diagnostic testing in hemoglobinopathies. A variety of novel methods of hemoglobinopathy
testing are now available at select laboratories in high‐resource areas. These newer techniques
expand the analysis and complexity of hemoglobinopathy testing and identification. Techni‐
ques include molecular methods of identification, such as the linear array assay, a multiplexed
reverse dot blot genotyping method, used to simultaneously test for a panel of common beta‐
globin variants (Hb S, C, E, D and O), as well as majority (>95%) of common beta‐thalasse‐
mia mutations1. Another newer method uses multiplex gap PCR assays to detect common
alpha thalassemia deletion mutations, alpha globin gene duplications and other globin gene
deletions, such as Hb Lepore and HPFH. Finally, DNA sequence analysis of alpha, beta or
gamma globin genes can also be performed to definitively identify unknown point mutations
or sequence variation. At present, however, these more advanced techniques remain seques‐
tered in advanced laboratories and are not universally available.
1 (http://www.rbclab.com/Pages/200/220/116%20LA/220%20116.html)
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Type of test Method Results PRO CON
Traditional testing methods
Isoelectric
focusing
Agarose gels to
separate
hemoglobin based
on isoelectric
points
Hb A, Hb F, Hb C,
Hb S, Hb E and
Hb OArab
Reliable, able to
distinguish most types
of sickle cell disease
including compound
heterozygotes
Expensive, requires
skilled technicians, often
batched and run every
few days
High‐performance
liquid
chromotography
Separates
hemoglobin by
principles of cation
exchange
Identify and quantify
Hb F, Hb A, Hb A2,
Hb S, Hb C, Hb Barts
and others
Reliable, able to
distinguish most types
of sickle cell disease,
including compound
heterozygotes
Expensive, requires
skilled technicians, often
batched and run
Hemoglobin
electrophoresis
Separates Hb
based on size and
charge
Identify and quantify
HbF, Hb A, Hb A2, Hb
S, Hb C, Hb Barts and
others
Reliable, able to
distinguish most types
of sickle cell disease
including compound
heterozygotes
Expensive, requires
skilled technicians, often
batched and run
Novel diagnostic testing methods
AMPS Density based test
to separate Hb in
different density
fluids
Identifies Hb S and Hb
A
Inexpensive, done at
the point of care
Interpretation is more
difficult, Less reliable
results, difficult to
distinguish HbSC
disease
Paper‐based
Sickle test
Microfluidic
assessment
Identifies Hb S and A
and C and company
has a separate test
that can identify Hb F
Inexpensive, done at
the point of care, reliable
diagnosis of HbSS
disease, easily
performed by
non‐skilled
personnel
Requires a scanner for
final results, can be
difficult to distinguish
HbAS (trait) from HbSC,
test could be altered in
different humidities
Sickle SCAN Lateral flow assay Distinguishes Hb A,
Hb S, Hb C
Reliably identifies HbA,
HbS, and HbC, easily
performed by non‐
skilled personnel, easily
interpreted, rapid test
at the point of care
More expensive than the
other point of care tests
above. Does not identify
hemoglobin F. Limit of
detection of Hb A is 2%
HemeChip Micro‐
elecrophoresis
assay
Distinguishes Hb F,
S, C, A, and D
Reliable, able to
distinguish most types
of sickle cell disease
including compound
heterozygotes
Requires a skilled
interpretation, web‐
based image processing
application for
automated results
Table 1. Hemoglobinopathy testing methods.
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3. Centralized laboratory efforts in low‐resource settings
In regions of the world where sickle cell trait and SCD are very prevalent, partnership be‐
tween private and public organizations and researchers and local hospitals has resulted in
impressive newborn screening/diagnostics for SCD. Examples of such efforts include Ango‐
la, Uganda and Jamaica.
3.1. Angola
Angola's newborn screening program for SCD was born out of the government mandated
public health initiative for perinatal HIV screening and a partnership with Chevron. Chevron
is one of the leading producers of petroleum in Angola. Thus, Chevron provides support for
many Angola‐based health initiatives. This initiative was undertaken in partnership with a US
academic hospital to assess whether a centralized newborn screening program for SCD was
feasible in a low‐resource setting. Additional emphasis in this initiative was placed on local
training and capacity building for the region. The laboratory was set up in the only pediatric
hospital in Angola, and the program was designed to send all collected samples to this location
for analysis [15].
For the pilot program in Angola, researchers selected two large maternity hospitals in Luanda
as initial sites of blood collection from newborn infants. To enhance local capacity building,
obstetrical nurses were trained in the techniques of blood collection and then retrained
monthly, and then retrained approximately once a month. All samples were drawn using a
heel stick procedure to fill bloodspots on a custom‐designed Whatman screening card.
Individual cards were distinguished by unique barcodes linked to a database containing
necessary demographic information. Additionally, a detachable portion of the card was
provided to the mother. Bloodspots were dried and placed in a plastic bag for storage until
specimen pickup, as all testing was performed at the central laboratory.
Isoelectric focusing (IEF, RESOLVE® neonatal hemoglobin system, PerkinElmer, Inc.) was used
to perform testing of the dried bloodspot samples within one to two days of arrival in the NBS
laboratory. Samples were batched for testing (as done in the USA). Once resulted, the samples
were scored first by the laboratory technician and the laboratory supervisor subsequently
scored each gel independently to ensure accuracy of results. All IEF results with an FAS, FS or
other abnormal hemoglobin patterns, or in the rare instance of an indeterminate result, were
selected for repeat analysis by capillary electrophoresis (CE).
Attempts were made to contact all families of all newborns with HbSC or HbSS results between
6 and 8 weeks of age. Attempted contact was made by telephone. If the family could be reached,
infants had repeat samples drawn for confirmatory testing and enrollment in the local sickle
cell clinic. However, due to the low‐resource area and limited telephone access, 46% of families
of infants (with +tests) could not be contacted highlighting the difficulties of centralized
laboratory testing in low‐resource areas [15, 16].
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3.2. Uganda
Similar to Angola, the Ugandan Ministry of Health already had an active program for
prevention of mother‐to‐child transmission of HIV based on identifying and treated infected
mother and exposed newborns. It identifies and treats infected mothers and their exposed
infants. For this program, dried blood spots are collected from exposed infants at health‐care
facilities across the country, carried by motorcycle to laboratory hubs at the subdistrict level,
and shipped by courier to the Central Public Health Laboratories in the capital. A sickle cell
laboratory was initiated within the same central public health laboratories to test for normal
and abnormal hemoglobin. Also like Angola, the initiation of the sickle cell NBS program was
initiated through a partnership between a US academic center and the local hospital and
ministry of health [17–19].
The laboratory methods for sickle cell disease in Uganda were the same as those discussed in
Angola. Again, local staff at the Central Public Health Laboratories received on‐site training
by a technical, US‐based team on the study protocol, isoelectric focusing procedures and
interpretation of results. Additional sessions and re‐teaching sessions were also provided as
well as ongoing laboratory support. The system for reporting positive results in Uganda was
more advanced than that of Angola. Here, the hemoglobin results were communicated to the
collection sites with the existing HIV notification system [20].
3.3. Jamaica
Jamaica initiated newborn screening in 1973 with the development of the well‐described
Jamaican Sickle Cell Cohort Study. In this initial effort, 100,000 consecutive live births were
screened at the main Government Maternity Hospital (Victoria Jubilee Hospital, Kingston).
Obstetric and labor nurses were trained to collect cord blood specimens, and self‐adhesive
labels were provided in every labor ward. These labels were duplicated and consecutively
numbered so that identical labels were applied to the blood tube and a data card for each
patient. The blood tubes were stored at room temperature, collected each morning. These were
utilized to form hemolysates which were then used for hemoglobin electrophoresis [21, 22].
Following this initial work, Jamaica initiated a second centralized screening program in 1995
including both the main Government Maternity Hospital in Kingston (Victoria Jubilee
Hospital) as well as both the University Hospital of the West Indies, Kingston (added in 1997)
and the Spanish Town Hospital (added in 1998) to include 43% of births in Jamaica. Cord blood
samples were collected at birth on a Guthrie card instead of in tubes as done in the initial study.
All hemoglobin electrophoresis testing was performed by the newborn screening program at
the Sickle Cell Unit (SCU), Tropical Medicine Research Institute, Jamaica. Patient demograph‐
ics were collected with the Guthrie card and recorded in the newborn screening database. After
testing was completed, infants with positive screening results suggestive of a hemoglobinop‐
athy or with an inappropriate specimen or unclear results were notified by letter to come in
for confirmatory testing. For those babies who fail to come in, a research nurse found them to
encourage parents to bring their infant to the SCU for further testing.
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From 1995 to 2006, 150,803 infants had undergone cord blood screening and approximately
889 infants had phenotype results suggestive of possible SCD in the initial testing [3].
While the efforts described above are successful, they rely on a significant amount of govern‐
ment or partnership support to establish the infrastructure needed for testing patients,
confirming the diagnosis and re‐identifying/contacting the affected families. Additionally, a
large enough patient population is needed within specific areas to justify the cost of this type
of infrastructure. Thus, it remains a priority to validate a POC testing device for the diagnosis
of SCD.
4. Point‐of‐care testing for SCD
4.1. Methodology
To be an effective diagnostic test at the point of care (POC), all testing methods/devices must
contain some similar properties. By definition, POC testing requires that testing must occur at
or near the site of patient care. The goal of POC is to improve medical and economic outcomes
by promoting rapid response and faster therapeutic turnaround time which requires rapid
testing in close proximity to the patient. POC tests should also be simple. “Simple” means that
the device/test uses unprocessed samples, is easy to read and interpret, does not require
medical personnel for testing and includes instructions for confirmatory testing when needed.
The test must demonstrate “insignificant risk of erroneous result” through risk analysis which
can be overcome for hemoglobinopathy testing through the obligation to perform confirma‐
tory testing. Finally, one of the advantages of diagnostic POC testing is the opportunity for
immediate feedback for the patient [23, 24]. A POC gives the tester (or clinician) the capability
to interact at the time of testing, taking advantage of the counseling and educational oppor‐
tunity.
These devices must have high specificity to detect HbS (including in the presence of hemo‐
globin F), the capacity to distinguish sickle cell trait (HbAS) from samples with SCD. These
point‐of‐care testing methods for SCD and sickle cell trait must be scalable, portable and easy
to use. Results must be available within the same visit/time period for the affected patient (no
follow‐up required to receive tests results). For low‐resource areas, devices need to be low cost,
compact, and light weight to enhance portability. Finally, testing must be easy to perform with
a simple design and rapid interpretation that does not require complex evaluation (i.e., does
not require a medical professional) [25, 26].
4.1.1. POC tests in development
There are several testing methods and devices currently in development to achieve the aims
above. These tests rely in different ways on the pathophysiologic properties of the sickle
hemoglobin that differentiate it from other hemoglobin. While this list likely not exhaustive,
it includes the current published tests in development. The testing methods are in various
stages of evaluation and validation, and many companies and individuals are seeking device
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agency approvals. Current testing methodologies are listed in Table 1 and include in the
following.
4.2. Density‐based test
One of the main properties of cells containing hemoglobin S is that these cells sickle upon
deoxygenation. The degree of sickling is relative to the quantitative amount of S hemoglobin
within the red cell. As cells sickle, this increases their density which allows red blood cells
(RBCs) containing hemoglobin to be separated by cell density. Red blood cells in SCD have a
specific distribution of cell densities which can be distinguished using Aqueous Multiphase
Systems (AMPS). This system includes a combination of polymers and/or surfactants in water
than form distinct, immiscible phases which allows the separation of cells based on density.
For this testing device, whole blood must be centrifuged and separated into components prior
to the red cells being placed in the AMPS solution. To allow for centrifugation in low‐resource
areas, investigators have identified battery operated mini‐centrifuges capable of successfully
separating the red cell fragment and allowing for testing. Devices are stable and densities can
be tuned to distinguish very small differences (Δρ ∼0.0005 g/cm3). However, potential
negatives include difficult in interpretation in the field and inability to successfully distinguish
hemoglobin SC disease (Figure 1) [27, 28].
Figure 1. AMPS‐based sickle cell disease POC test [27].
4.3. Microfluidic‐paper‐based test
Paper‐based testing utilizes similar methodology to conventional hemoglobin solubility assays
(e.g. SickleDex™, SA and ASI test), which have been used routinely by blood banks and clinical
laboratories to verify the presence of HbS in blood samples for many years [10]. When
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deoxygenated, sickle hemoglobin forms polymers, which are more soluble in solution. Specific
solubility buffers contain:
1. Saponin irreversibly lyses red blood cells (RBCs) by creating holes in the lipid bilayer that
releases hemoglobin into the buffer.
2. Sodium hydrosulfite converts the released hemoglobin into deoxy‐Hb that is either
soluble (HbA, HbE, HbF or HbC) or insoluble (HbS) in the phosphate buffer.
When these solutions of hemolyzed samples are placed on paper, the delay in transit time
caused by the sickle polymers results in a characteristic blood stain pattern which distinguishes
normal, sickle cell trait and SCD samples. In other words, paper‐based assay identifies the
presence of HbS by measuring the separation of HbS from non‐HbS by differential wicking/
transit of insoluble Hb S vs. soluble Hb in a paper matrix. Blood stain patterns are produced
on the chromatography paper based on solubility. However, instead of measuring turbidity
(as in Sickledex test), the paper blood stain reflects the amount of polymerized HbS trapped
within the paper fibers while the soluble (non‐polymerized) hemoglobin continues to spread
on the paper. Because hemoglobin is naturally colored, the assay read out uses the red color
count in the region of the polymerized hemoglobin and soluble hemoglobin [29].
Testing results (the blood stain) can then be scanned using portable scanners (on a cell phone)
to quantify the density of the blood stain and differentiate SCD vs SC trait vs. sickle SC disease.
However, this test remains dependent on a low percent of fetal hemoglobin which makes it
less ideal in newborn screening. A newer version of the test in development may resolve this
complication but results are pending at this time. This device successfully reduces the required
blood sample volume, lowering the per‐test cost and significantly simplifying the interpreta‐
tion of results. Sickle cell anemia can be distinguished easily but scanning is required for further
hemoglobin differentiating. Scanned results are easy to interpret which makes the test highly
adaptable in the non‐medical population (Figure 2) [30].
Figure 2. Characteristic blood stain patterns produced by paper‐based SCD assay.
4.4. Lateral flow assays
Lateral flow assays are simple devices intended to detect the presence (or absence) of a target
analyte. For this type of test, the analyte is hemoglobin. Antibodies are utilized to bind to the
human alpha globin chain and are conjugated to colored nanoparticles. These antibodies are
conjugated to yellow‐colored nanoparticles bind the antigen (Hb) as they migrate toward the
Point‐of‐Care Testing in Sickle Cell Disease
http://dx.doi.org/10.5772/64862
61
test lines. Conjugated antibodies with bound Hb (antigen) bind to capture antibodies (poly‐
clonal antibodies for specific hemoglobin S, C, A) on each of three test lines (producing positive
result). Nanoparticles without antigens bind to the control line (proof of validity of the testing
device) (Figure 3) [32].
Figure 3. (a–d) Lateral testing method [31].
Current tests in development utilize polyclonal antibodies that can bind to hemoglobin S, C,
A and F. The result is a single test line for each specific hemoglobin (identifying the presence
of that particular hemoglobin). Importantly, this type of test is electricity/battery free, can be
performed with capillary whole blood that does not require centrifugation and produces rapid
results. Because lateral flow tests can demonstrate the result of more than one hemoglobin at
a time, these devices can also detect heterozygotes (patients carrying two or more distinctive
hemoglobin or patients who have been transfused with a differing hemoglobin).
4.5. HemeChip (micro‐electrophoresis assay)
The newest published device for point‐of‐care testing in SCD is a small version of a hemoglobin
electrophoresis. Minimal amount of blood (from a capillary stick) is required and placed on a
piece of cellulose paper in alkaline buffer. The paper is then inserted into a device (Figure 4)
that houses a micro‐engineered plastic chip for cellulose acetate electrophoresis and uses a
battery powered electric field to separate hemoglobin based on charge as described in standard
hemoglobin electrophoresis. The result requires image quantitation using an intensity‐based
application on a mobile phone image. Results validated against standard EP and HPLC with
correlation >0.96 for all hemoglobin tested including the ability to distinguish Hb F, S, C, A, D.
This test utilizes the principles of electrophoresis to detect and distinguish hemoglobin based
on the traveling distance from the sample application point and displays quantitative %
hemoglobin fractions. A web‐based image processing application for automated and objective
quantification of HemeChip results at the POC using cloud computing resources [33].
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Figure 4. (a–c) Hemechip [33].
5. Discussion
Multiple point‐of‐care tests are currently in development for the identification of sickle cell
disease at the point of care. It is important for confirmatory hematology testing, a multiplex
device should be available for clinicians to make proper clinical assessments. As discussed,
the device and method must distinguish target hemoglobin from interfering substances in
blood that cause false‐positive or negative results. It is clear that the pathophysiology of SCD,
specifically the point mutations in the genome leading to the hemoglobin expression and the
polymer formation that occurs upon cellular dehydration have been well utilized in the design
of these testing devices. The optimal testing method will be the device that can produce at the
lowest cost, easily utilized in a low‐resource setting, with easy‐to‐interpret results and low
false‐negative results.
Based on the testing method described above, the lateral flow test is currently the most easily
utilized in the field without requiring specialists for interpretation. This test has the capacity
to clearly distinguish the majority of hemoglobin within a rapid period of time. However, it is
unclear whether lateral flow tests will be cost prohibitive for widespread use. Alternatively,
the Hemechip provides an excellent method for sickle cell disease confirmation also easily
utilized in point‐of‐care settings although the interpretation requires additional skill as well
as the use of mobile phone and internet access.
6. Conclusions
There are significant therapeutic and diagnostic health disparities that exist between SCD and
other, inherited and acquired health conditions. Recent literature demonstrates that point‐of‐
care diagnostics for sickle cell disease are feasible and accurate. Thus, it is hopeful that novel
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point‐of‐care diagnostics will change the screening paradigm for some areas in which central
lab testing is not available.
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